Financial pressures stemming from shifting markets and the effects of recent terrorist activities have spurred reorganization at Analogic. Company efforts will be split between two major business groups: OEM advanced technology subsystems and systems,
Financial pressures stemming from shifting markets and the effects of recent terrorist activities have spurred reorganization at Analogic. Company efforts will be split between two major business groups: OEM advanced technology subsystems and systems, and niche market end-user products. Company founder Bernard Gordon, along with Donald Barry, group vice president and president of subsidiary SKY Computers, will focus on OEM medical imaging subsystems and systems. Tom Miller, Analogic president and CEO, will focus on niche market end-user activities involving subsidiaries B-K Medical, which specializes in surgical and urological ultrasound, and Camtronics Medical Systems, which specializes in cardiac image and information management. Miller will also oversee the sale or deactivation of certain mature business operations. Julian Soshnick will take over as vice president and general counsel upon the departure of Gene Bauer. Lothar Koob, executive vice president, and John Millerick, chief financial officer, will work closely with Gordon and Miller. The reorganization promises to allow the company to capitalize on the potential for security devices, particularly those designed to detect explosives. It may also help offset the effects of business lost because of consolidation within the imaging industry, which affects sales of CT components, and a severe decline in the communications and semiconductor markets.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.